PD testing of clinical COVID-19 Study at VelaLabs

At the beginning of April, the Austrian company APEIRON Biologics AG announced that it has initiated a Phase II clinical trial of APN01 in Austria, Germany and Denmark to treat COVID-19. APN01 is the recombinant form of the human angiotensin-converting enzyme 2 (rhACE2), which has the potential to block the infection of cells by the novel SARS-CoV-2 virus. The clinical trial will treat 200 severely infected COVID-19 patients. From many competitors, VelaLabs was selected to support the analysis of the patient samples of the study. In short time frames six samples will be taken from every patient and tested immediately at the VelaLabs facilities. This summer (2020), the evaluation is expected to be finalized at latest.The team of VelaLabs is proud to be a part of the world-wide fight against the SARS-CoV-2 pandemic.

The sender takes full responsibility for the content of this news item. Content may include forward-looking statements which, at the time they were made, were based on expectations of future events. Readers are cautioned not to rely on these forward-looking statements.

As a life sciences organization based in Vienna, would you like us to promote your news and events? If so, please send your contributions to news(at)lisavienna.at.